newsfilter
← Latest News
PR Newswire·

Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the FDA has granted an orphan drug...